Rejuvenate Bio

Private

San Diego-based gene therapy company developing longevity and age-related-disease treatments. Initial pipeline in companion animals (dogs) targeting eventual human applications. Three longevity gene targets: FGF21, sTGFβR2, αKlotho. Spinout from George Church's Harvard/Wyss Institute lab. Founded 2018.

Founders Daniel Oliver, Noah Davidsohn

CEO Daniel Oliver

Company

Founded

2018

Headquarters

San Diego, USA

Financials

Total Funding

$16M

Sectors

Healthtech Biotech

rejuvenatebio.com

Funding History

2 rounds

Series B Jun 8, 2026

$6M

VCapital (Lead) Merck Animal Health Kendall Capital Partners Connecticut Innovations Digitalis Ventures

Series A Jun 1, 2023

$10M

Digitalis Ventures (Lead)

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.